Keyvan Karimi Galougahi

Dr. Keyvan Karimi Galougahi


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2017 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
KGKeyvan Karimi Galougahi
Keyvan Karimi Galougahi
GMGary S. Mintz
Gary S. Mintz
DKDimitri Karmpaliotis
Dimitri Karmpaliotis
ZAZiad Ali
Ziad Ali

1 January 2022 in Korean Circulation Journal
Verified
Journal Article
Open access
PDF file
ZAZiad Ali
Ziad Ali
JEJavier Escaned
Javier Escaned
DDDariusz Dudek
Dariusz Dudek
JRJai Radhakrishnan
Jai Radhakrishnan
KGKeyvan Karimi Galougahi
Keyvan Karimi Galougahi
Korean Circulation Journal 대한심장학회지 순환기 Ali ZA, et al. Korean Circ J. 2022 Jun;52:e65. https://doi.org/10.4070/kcj.2022.0093

17 October 2018 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
MYMyong Hwa Yamamoto
Myong Hwa Yamamoto
AMAkiko Maehara
Akiko Maehara
SKSung Sik Kim
Sung Sik Kim
KKKohei Koyama
Kohei Koyama
SKSong‐Yi Kim
Song‐Yi Kim
RSRichard A. Shlofmitz
Richard A. Shlofmitz

1 January 2022 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
TSTariq Jamal Siddiqi
Tariq Jamal Siddiqi
Muhammad Shahzeb KhanMuhammad Shahzeb Khan
Muhammad Shahzeb Khan
KGKeyvan Karimi Galougahi
Keyvan Karimi Galougahi
ESEvan Shlofmitz
Evan Shlofmitz
JMJeffrey W. Moses
Jeffrey W. Moses
ZAZiad A. Ali
Ziad A. Ali

27 November 2021 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
KGKeyvan Karimi Galougahi
Keyvan Karimi Galougahi
A healthy 29-year-old male received the first dose of the ChAdOx1-nCoV-19 vaccine (AstraZeneca). Four-days post-inoculation, he noted intermittent paraesthesia in extremities, which gradually became persistent. He was completely asymptomatic prior to the inoculation, with no fever, cough, shortness of breath, or gastrointestinal symptoms, including since receiving the vaccine. There was no family history of autonomic neuropathy. Clinical examination, including neurologic exam, was normal. Blood count, electrolytes, inflammatory markers, thyroid function, and folate were normal. Polymerase chain reaction assay for COVID-19 was negative. B12 was mildly low [161 ng/L (200–1000)] with a negative intrinsic factor antibody. He was started on B12 injections and Amitriptyline for neuralgia. His symptoms, nevertheless, persisted. Two months post-inoculation, he noted increased heart rate on smartwatch (Apple Inc., Figure 1A), with a significant change when standing (80–120 b.p.m.) vs. lying (50–60 b.p.m.). He then developed intermittent skin colour changes (dark-blue/white/dark-red) in acral areas (hands/feet/penis), with mottling and blood pooling/dependent acrocyanosis with sluggish capillary refill ( Figure 1B and C). He had intermittent palpitations, dizziness, and worsening of paraesthesia and skin colour changes especially with prolonged standing, exertion, food intake, or changes in the temperature in the environment, with no pre-syncope or syncope. He also developed difficulty achieving and maintaining an erection.

10 April 2021 in Cells
Verified
Journal Article
Open access
PDF file
CKChinmay Khandkar
Chinmay Khandkar
MMMahesh V. Madhavan
Mahesh V. Madhavan
JWJames C. Weaver
James C. Weaver
DCDavid S. Celermajer
David S. Celermajer
KGKeyvan Karimi Galougahi
Keyvan Karimi Galougahi
The atherothrombotic substrates for acute coronary syndromes (ACS) consist of plaque ruptures, erosions and calcified nodules, while the non-atherothrombotic etiologies, such as spontaneous coronary artery dissection, coronary artery spasm and coronary embolism are the rarer causes of ACS. The purpose of this comprehensive review is to (1) summarize the histopathologic insights into the atherothrombotic plaque subtypes in acute ACS from postmortem studies; (2) provide a brief overview of atherogenesis, while mainly focusing on the events that lead to plaque destabilization and disruption; (3) summarize mechanistic data from clinical studies that have used intravascular imaging, including high-resolution optical coherence tomography, to assess culprit plaque morphology and its underlying pathobiology, especially the newly described role of innate and adaptive immunity in ACS secondary to plaque erosion; (4) discuss the utility of intravascular imaging for effective treatment of patients presenting with ACS by percutaneous coronary intervention; and (5) discuss the opportunities that these mechanistic and imaging insights may provide for more individualized treatment of patients with ACS.